Abstract 2154P
Background
The role of lipid levels in the development and outcomes of cancer patients remains unclear in the literature. In this study, we aimed to analyze whether there is a relationship between total cholesterol levels and the survival of hospitalized cancer patients.
Methods
This retrospective observational study included patients admitted to the Medical Oncology Hospitalization Unit at La Paz University Hospital between September 2018 and January 2020. Total cholesterol levels, tumor type, treatment received, and mortality were analyzed.
Results
A total of 839 patients were included, with no differences in gender distribution. The most frequent tumor was lung (20.7%), followed by digestive tumors, including colorectal, esophagogastric, pancreatobiliary, or hepatic (33.4%), and breast (11.4%). The majority of patients were receiving active cancer-specific treatment, with chemotherapy (51.5%) or targeted treatments (18.6%) at the time of admission. At the end of the median follow-up period (31,8 months), 615 deaths had occurred (78.9%). The median overall survival (OS), regardless of tumor type, was 199 days. Having low total cholesterol values (less than 150 mg/dL) increased the risk of mortality by 25.9% compared to having physiological levels (150-200 mg/dL) (p=0.016, CI95% 1.045, 1.518)) with a Hazard Ratio of 1.259. Having high total cholesterol values (above 200 mg/dL) increased the risk of mortality by 30.6% compared to having physiological levels (p=0.036, CI95%(1.017, 1.677)) with an HR of 1.306.
Conclusions
To date, the majority of studies indicate that elevated cholesterol levels in patients with advanced cancer are associated with a higher risk of mortality, both due to a higher burden of comorbidity and the potential effects of cholesterol on oncogenic pathways. On the other hand, low cholesterol levels, possibly reflecting a significant metabolic dysregulation during cachexia, seem to be linked to a worse prognosis as well. Although the mechanisms by which high or low cholesterol levels increase the risk of mortality may differ, their incorporation into prognostic scores can contribute to a more accurate estimation of prognosis in advanced patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2173P - Exploring the complex needs of older patients receiving targeted therapies and immune checkpoint inhibitors for renal and skin cancers at the Royal Marsden Hospital
Presenter: Niamh Cunningham
Session: Poster session 07
2174P - The impact of exposure to antibiotic (ATB) and proton pump inhibitor (PPI) therapy on immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study
Presenter: Lawson Eng
Session: Poster session 07
2175P - Sex and age-related differences in immunotherapy-induced toxicities
Presenter: Mafalda Teixeira da Costa
Session: Poster session 07
2176P - Rechallenge of immune checkpoint inhibitors after immune-related adverse events: A systematic review
Presenter: Jin Young Kim
Session: Poster session 07
2177P - Immunotherapy adverse events association with inflammation scores: A real-world data analysis from a Portuguese hospital
Presenter: Catarina Fernandes
Session: Poster session 07
2179P - Prospective monitoring of autoimmune events in cancer immunotherapy patients: A report on the first 658 patients in the PRAISE study
Presenter: Eden Sebbag
Session: Poster session 07
2180P - Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients
Presenter: Víctor Albarrán
Session: Poster session 07
2181P - Effect of different corticosteroid treatment strategies on checkpoint inhibitors pneumonitis outcomes
Presenter: Hui Guo
Session: Poster session 07
2182P - Patient involvement to improve prospective follow-up: Quality of life data after cancer immunotherapy from the PRAISE study
Presenter: Eden Sebbag
Session: Poster session 07
2183P - The relevance of HFpEF in immunotherapy-induced myocarditis: An analysis of 65 patients
Presenter: Adam Chapman
Session: Poster session 07